^
    1d
    Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, Rutgers, The State University of New Jersey | Not yet recruiting --> Recruiting
    Enrollment open • Biomarker assay • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab)
    1d
    CAR2BRAIN: Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma (clinicaltrials.gov)
    P1, N=42, Recruiting, Johann Wolfgang Goethe University Hospital | Active, not recruiting --> Recruiting | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Dec 2025 --> Dec 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    ezabenlimab (BI 754091) • HER2 t-haNK
    1d
    GEMINI-PeriOp GC: A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=100, Recruiting, AstraZeneca
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 positive • HER-2 negative • CLDN18.2 positive • CLDN18.2 positive + HER-2 negative
    |
    docetaxel • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936)
    2d
    Demonstration Project on the Use of Trastuzumab for Injection in HER2-Positive Breast Cancer (ChiCTR2600121381)
    P=N/A, N=3245, Zhongshan Hospital Fudan University; Zhongshan Hospital Fudan University
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab)
    2d
    A single-arm, phase II, exploratory study of neoadjuvant treatment with Kudosil combined with Culmerciclib and dual-targeted therapy of trastuzumab and pertuzumab in HR+, HER2+ breast cancer (ChiCTR2600121242)
    P2, N=28, Recruiting, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital); The First Affiliated Hospital of Nanjing Medical U
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • letrozole • Saitanxin (culmerciclib)
    2d
    Trastuzumab and pertuzumab in combination with eribulin mesylate as neoadjuvant therapy for early or locally advanced HER2-positive breast cancer: a prospective, single-arm, phase II clinical trial (ChiCTR2600120346)
    P4, N=40, Recruiting, The First Hospital of Jilin University; The First Hospital of Jilin University
    New P4 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 amplification • HER-2 expression
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • Halaven (eribulin mesylate)
    2d
    A Multicenter, Open-Label, Randomized, Phase II Clinical Trial of Trastuzumab Rezetecan-based Therapy for Brain Metastases in HER2-Positive Breast Cancer (ChiCTR2600120221)
    P2, N=108, ChongQing university cancer hospital; ChongQing university cancer hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • Focus V (anlotinib) • capecitabine • Irene (pyrotinib) • trastuzumab rezetecan (SHR-A1811)
    2d
    Transformation to the TCbHPy regimen for early or locally advanced HR-/HER2+ breast cancer patients insensitive to 2 cycles of TCbHP neoadjuvant therapy：A prospective, exploratory, phase II, multicenter study (ChiCTR2600119838)
    P2, N=171, Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (The First Affiliated Hospital wi
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    2d
    Observational study on the combination of fruquintinib and standard chemotherapy in the treatment of advanced gastric cancer (ChiCTR2600119681)
    P=N/A, N=50, Completed, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
    New trial
    |
    HER-2 positive
    |
    Fruzaqla (fruquintinib)
    2d
    A Prospective, Multicenter, Single-Arm Clinical Study of Atezolizumab Combined with SHR-A1811and Pertuzumab in the Neoadjuvant Treatment of HER2-Positive Breast Cancer (ChiCTR2600118900)
    P2, N=50, The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Tecentriq (atezolizumab) • Perjeta (pertuzumab) • trastuzumab rezetecan (SHR-A1811)
    2d
    A Randomized, Open-Label Trial of Trastuzumab Combined with Pyrotinib and Taxanes (THPy) versus Trastuzumab Combined with Pertuzumab and Taxanes (THP) as First‑Line Treatment for Advanced HER2‑Positive Breast Cancer (ChiCTR2500101511)
    P4, N=568, Recruiting, Anhui Provincial Cancer Hospital; Anhui Provincial Cancer Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • Irene (pyrotinib)
    2d
    Real-World Study on the Prognostic Impact of PIK3CA Mutations in Patients with HER2-Positive Advanced Breast Cancer (ChiCTR2500113318)
    P=N/A, N=200, Recruiting, The First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Wenzhou Medical University | Not yet recruiting --> Recruiting
    Enrollment open • Real-world evidence
    |
    HER-2 positive